Victoria Socha

DocwireNews

Erythropoiesis-stimulating agents (ESAs) in combination with iron supplementation have been the mainstay of treatment of anemia in chronic kidney disease (CKD) for the past 30 years. While treatment for patients with <a href="https://www.docwirenews.com/latest-nephrology-news/online-cme-improves-knowledge-of-emerging-treatments-for-anemia/">anemia</a> of CKD with ESAs is highly efficacious, results of clinical trials have shown an association between the use of ESAs with a high hemoglobin target and increased risk of cardiovascular events. The resulting safety concerns have raised interest in development of an alternative therapeutic strategy.Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) have emerged as novel treatments for anemia in CKD. The mechanism of action of HIF-PHIs is stimulation of endogenous erythropoietin production via HIF activation and induction of erythropoiesis. Mai Sughara, MD, and colleagues provided an overview of the future of the agents in Pharmacology &amp; Therapeutics [doi.org/10.1016/j.pharmthera.2022.108272].To date, at least six small-molecule HIF-PHIs have been developed. Results of phase 3 clinical trials have demonstrated that the effect of HIF-PHIs is noninferior to ESAs. The new agents may offer several advantages over conventional treatment, including an oral route of administration and the ability to raise hemoglobin levels in patients with chronic inflammation.While many of the phase 3 trials demonstrated that HIF-PHIs were noninferior to placebo or ESAs regarding cardiovascular safety, one of the compounds failed to meet the prespecified noninferiority criterion in non-dialysis-dependent CKD patients. In some studies, another a HIF-PHI appeared to be associated with potential risks for thromboembolic events.The regulatory agencies of some countries, including Japan and the European Union, concluded that roxadustat, one of the HIF-PHIs in development, had a favorable benefit-risk profile. The US FDA opted not to approve roxadustat due to safety concerns.&ldquo;To establish the optimal anemia management for CKD, further studies are needed to evaluate important aspects of HIF-PHIs, such as long-term safety , appropriate hemoglobin target, and the types of patients who would gain benefits from these new drugs,&rdquo; the researchers said.

Jordana Jampel

Glycan-Targeting Novel Vaccine Shows Promise for Vast Virus Protection

Infectious Disease

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Latest News

HIF-PHIs for Anemia in CKD: An Overview

Chronic Kidney Disease

Erythropoiesis-stimulating agents (ESAs) in combination with iron supplementation have been the mainstay of treatment of anemia in chronic kidney disease (CKD) for the past 30 ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe